Cullinan Therapeutics (NASDAQ:CGEM) and Calidi Biotherapeutics (NYSE:CLDI) Head to Head Contrast

Cullinan Therapeutics (NASDAQ:CGEM) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Cullinan Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cullinan Therapeutics and Calidi Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	$18.94 million	49.35	-$153.16 million	($2.84)	-5.68
Calidi Biotherapeutics	$50,000.00	473.29	-$29.22 million	N/A	N/A

Calidi Biotherapeutics has lower revenue, but higher earnings than Cullinan Therapeutics.

Profitability

This table compares Cullinan Therapeutics and Calidi Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-28.04%	-26.67%
Calidi Biotherapeutics	N/A	N/A	-219.07%

Insider and Institutional Ownership

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 6.1% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 24.3% of Calidi Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Cullinan Therapeutics and Calidi Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	0	0	7	0	3.00
Calidi Biotherapeutics	0	0	3	0	3.00

Cullinan Therapeutics currently has a consensus price target of $31.67, suggesting a potential upside of 96.44%. Calidi Biotherapeutics has a consensus price target of $16.67, suggesting a potential upside of 682.47%. Given Calidi Biotherapeutics’ higher possible upside, analysts plainly believe Calidi Biotherapeutics is more favorable than Cullinan Therapeutics.

Summary

Calidi Biotherapeutics beats Cullinan Therapeutics on 6 of the 10 factors compared between the two stocks.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.